

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS VIII, LLC

Petitioner,

v.

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Patent Owner

Case: IPR2015-01836

Patent No. 7,932,268

**DECLARATION OF FRANK SACKS, M.D., IN SUPPORT OF PATENT
OWNER'S RESPONSE TO PETITION FOR *INTER PARTES* REVIEW
AND IN SUPPORT OF MOTION TO AMEND**

TABLE OF CONTENTS

	<u>Page</u>
I. QUALIFICATIONS	4
II. INFORMATION CONSIDERED.....	14
III. SUMMARY OF OPINIONS.....	14
IV. LEGAL PRINCIPLES.....	17
V. RELEVANT DATE OF INVENTION, PERSON OF ORDINARY SKILL IN THE ART, AND CLAIM CONSTRUCTION	20
A. Date of Invention.....	20
B. Person of Ordinary Skill in the Art	20
C. Claim Construction.....	22
VI. THE PATENTS AT ISSUE	23
VII. BACKGROUND AND STATE OF THE ART.....	29
A. Hypercholesterolemia.....	29
B. Therapeutic Drugs for Hypercholesterolemia	29
1. Statins	30
2. Bile Acid Sequestrants	32
3. Nicotinic Acid	33
4. Fibrates	35
C. Differences Among the Statins	35
D. Use of Drug Therapy to Achieve Treatment Goals	38
E. Homozygous Familial Hypercholesterolemia.....	39
F. MTP Inhibitors	41
VIII. NO CHALLENGED CLAIM OF THE '135 OR '268 PATENT IS OBVIOUS OVER ANY COMBINATION OF PRIOR ART CITED BY THE PETITIONER IN GROUNDS 1 OR 2	44
A. A POSA Would Not Have Been Motivated to Combine Chang With Either Pink Sheet 2004 or Stein 2004, and These Combinations Would Not Have Given a POSA a Reasonable Expectation of Success that Substituting Lomitapide Into Dr. Stein's Protocol for Implipapide Would Have Resulted in a Means of Treating Patients in a Safe and Efficacious Manner.....	45

1. A POSA would not have been motivated to select lomitapide for development.....	45
2. Chang does not suggest that implitapide and lomitapide would have similar effects at similar doses.....	48
3. Titration to reduce side effects was not the norm for most cholesterol-lowering drugs, and a POSA would not have expected upward titration to reduce lomitapide’s side effects	56
4. Clinicians would not have used references like Pink Sheet or Stein to devise dosing regimens.....	64
5. A POSA would not have understood Dr. Stein to be proposing a method of treating patients via upward titration to ameliorate side effects.....	66
6. The results of Dr. Stein’s proposed experiment were unknown, so there was no indication that he was able to even find a therapeutic window for implitapide	68
B. Dependent Claims of the ’135 Patent.....	69
C. Dependent Claims of the ’268 Patent.....	71
D. Secondary Considerations	73
1. Long-Felt Need.....	73
2. Praise	76
3. Unexpected Results	76
4. Teaching Away.....	77
5. Failure of Others.....	79
IX. MOTION TO AMEND	80
A. The Proposed Substitute Claims Are Supported By the Written Description of the Provisional Application	80
B. The Proposed Substitute Claims Are Patentable Over All Prior Art of Record	103
X. PRIOR EXPERT TESTIMONY	104
XI. COMPENSATION	106

I, Frank Sacks, M.D., declare and state as follows:

I. QUALIFICATIONS

1. I am a Professor of Cardiovascular Disease Prevention in the Department of Nutrition at the Harvard T.H. Chan School of Public Health, a Professor of Medicine in the Channing Division of Network Medicine at Harvard Medical School, and Senior Physician at Brigham & Women's Hospital. My responsibilities include research, teaching, and previously clinical practice, all pertaining to hyperlipidemia, hypertension, and associated conditions in the prevention and treatment of cardiovascular disease (CVD). I also participate as a member, chair, or fellow in numerous professional societies, committees, and editorial boards.

2. My clinical field of expertise is lipidology, the diagnosis and treatment of lipid disorders including hypercholesterolemia (high blood cholesterol), hypertriglyceridemia (high blood triglycerides), and low high-density lipoprotein (HDL) cholesterol.

3. I am a fully licensed physician in the State of Massachusetts.

4. My professional interests include research and public policy in nutrition, cholesterol disorders, hypertension, and cardiovascular disease. I have 240 peer-reviewed publications of original research in peer-reviewed journals, including in journals such as the New England Journal of Medicine (NEJM) and

the Journal of the American Medical Association (JAMA), and over 90 reviews, editorials and chapters relating to my interests. In addition, I am the editor or co-editor of three books relating to cardiovascular disease, cholesterol disorders, and nutrition.

5. In 1970, I received a Bachelor of Science degree in Biology with an emphasis in Biochemistry from Brown University. From 1972 to 1973, I was a research assistant at the Channing Laboratory, Harvard Medical School, at which time I began research in nutrition and cardiovascular disease. In 1977, I received a Doctor of Medicine degree from Columbia University College of Physicians and Surgeons. From 1977 to 1978, I was a Resident in Surgery at University Hospital in Madison, Wisconsin. In 1978, I received a license to practice medicine in Wisconsin.

6. From 1978 to 1980, I was an emergency room physician at several hospitals in Wisconsin. From 1980 to 1982, I served as a Postdoctoral Research Fellow in the Department of Medicine at Harvard Medical School and Brigham and Women's Hospital concentrating on nutrition in the prevention and treatment of cardiovascular disease (CVD) and stroke. From 1982 to 1993, I had faculty appointments at Harvard Medical School, was employed at Brigham and Women's Hospital, and also had hospital appointments at Children's Hospital and Beth Israel Hospital, all in Boston and pertaining to diagnosis and

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.